Recro Pharma (NASDAQ: REPH) is a revenue generating specialty pharmaceutical company developing multiple non-opioid therapeutics for the treatment of acute post operative pain. Recro Pharma is currently developing IV/IM Meloxicam, a proprietary, Phase III-ready, rapid-onset, long-acting preferential COX-2 inhibitor, and Dex-IN, a proprietary intranasal formulation of dexmedetomidine in Phase II, both for the treatment of acute post operative pain. As Recro Pharma's product candidates are not in the opioid class of drugs, the Company believes its candidates would avoid many of the side effects associated with commonly prescribed opioid therapeutics, such as addiction, constipation and respiratory distress while maintaining analgesic effect. Recro Pharma owns and operates an 97,000 square foot, DEA-licensed facility that manufactures five commercial products that are commercialized by partners and receives royalties associated with the sales of these products. Source
No articles found.
LifeVantage Corporation (Nasdaq: LFVN) is a pioneer in Nutrigenomics - a new scien...
LifeVantage Corporation (Nasdaq: LFVN) is a pio...
Neon Therapeutics is a clinical-stage immuno-oncology company leading in the field...
Neon Therapeutics is a clinical-stage immuno-on...
Since Mannatechâs establishment in 1994, the company has pioneered a commitment ...
Since Mannatechâs establishment in 1994, the ...
We are a clinical stage biopharmaceutical company focused on the discovery, develo...
We are a clinical stage biopharmaceutical compa...
Spring Bank is a clinical-stage biopharmaceutical company engaged in the discovery...
Spring Bank is a clinical-stage biopharmaceutic...
Tricida, Inc. , Tricida, Inc. , is a pharmaceutical company focused on the develop...
Tricida, Inc. , Tricida, Inc. , is a pharmaceut...
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the ...
AcelRx Pharmaceuticals, Inc. is a specialty pha...
Join the National Investor Network and get the latest information with your interests in mind.